Aptamer-conjugated PLGA nanoparticles for delivery and imaging of cancer therapeutic drugs

Hashemi, Maryam; Shamshiri, Azarmidokht; Saeedi, Majid; Tayebi, Lobat; Yazdian‐Robati, Rezvan

doi:10.1016/j.abb.2020.108485

Cited by 50 publications

(19 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor cells may overexpress specific receptors, such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), folic acid (FA), integrin, CD44 (a cell surface glycoprotein), CD13, and prostate-specific membrane antigen [23]. According to these receptors, specific ligands, such as antibody [24], nuclear acid (e.g., aptamers [25]), protein (e.g., transferrin [26]), peptides (e.g., iRGD [27], iNGR [28]), small molecules (folic acid [29]), and carbohydrates (e.g., dextran, mannose, and galactose [30], targeting macrophages) were proposed for the surface modification of liposomes.…”

Section: Introductionmentioning

confidence: 99%

A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives

Liu¹,

Chen²,

Zhang³

2022

Molecules

386

239

View full text Add to dashboard Cite

Liposomes have been considered promising and versatile drug vesicles. Compared with traditional drug delivery systems, liposomes exhibit better properties, including site-targeting, sustained or controlled release, protection of drugs from degradation and clearance, superior therapeutic effects, and lower toxic side effects. Given these merits, several liposomal drug products have been successfully approved and used in clinics over the last couple of decades. In this review, the liposomal drug products approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are discussed. Based on the published approval package in the FDA and European public assessment report (EPAR) in EMA, the critical chemistry information and mature pharmaceutical technologies applied in the marketed liposomal products, including the lipid excipient, manufacturing methods, nanosizing technique, drug loading methods, as well as critical quality attributions (CQAs) of products, are introduced. Additionally, the current regulatory guidance and future perspectives related to liposomal products are summarized. This knowledge can be used for research and development of the liposomal drug candidates under various pipelines, including the laboratory bench, pilot plant, and commercial manufacturing.

show abstract

Section: Introductionmentioning

confidence: 99%

A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives

Liu¹,

Chen²,

Zhang³

2022

Molecules

386

239

View full text Add to dashboard Cite

show abstract

“…Nanoparticles made with biodegradable polymer represents the most promising carriers of therapeutic agents because of their multiple advantages over conventional drug delivery vehicles [ 34 , 35 ]. Among those polymers, PLGA have been widely used in the field of drug deliver because of its low toxicity and excellent biocompatibilities [ 36–38 ]. Therefore, in the present study, the PLGA was selected as carrier material for development of dual-drugs loaded nanoparticles.…”

Section: Discussionmentioning

confidence: 99%

Tumor targetable and pH-sensitive polymer nanoparticles for simultaneously improve the Type 2 Diabetes Mellitus and malignant breast cancer

Tang

Wen

et al. 2022

Bioengineered

View full text Add to dashboard Cite

In the recent study, we have developed novel tumor targetable and pH-sensitive PLGA nanoparticles co-loaded with camptothecin (CPT) and metformin (Metf) to simultaneously improve the Type 2 Diabetes Mellitus (T2DM) and malignant breast cancer. To improve the drug loading efficiency, the hydrophobic CPT was conjugated with PLGA polymer by the pH-sensitive hydrazone bonds (hyd). Then, the Metf was physically loaded into the hydrophobicity inner core of CPT-conjugated PLGA nanocomplex to form the dual drugs-loaded nanoparticles (NP/CPT-Metf). Furthermore, on the surface of NP/CPT-Metf was modified with tumor-homing CGKRK peptides to obtain the tumor targetable and pH-sensitive polymer nanoparticles (CNP/CPT-Metf). It was demonstrated that the developed CNP/CPT-Metf displayed sufficient sensitivity to the weak acidic tumor microenvironment. Besides, excellent ability of CNP/CPT-Metf to mediate accumulation of drugs in cells and tumor tissues finally in turn resulted in a signal enhanced anti-tumor effect. Furthermore, it was demonstrated as well that CNP/CPT-Metf was able of significantly alleviating the type 2 diabetes mellitus in diabetic mice. In summary, the developed multifunctional polymer nanoparticles might represent a promising strategy for simultaneously improve the T2DM and treat malignant breast cancer.

show abstract

“…Furthermore, the fabrication of aptamer is executed out of the biological systems, reducing the risk of bacterial or viral contaminations (Huang et al., 2021 ; Shigdar et al., 2021 ). To date, isolation of various aptamers has been accomplished to specifically target substances in cancer cells, including mucin 1 (MUC1), epithelial cell adhesion molecule (EpCAM), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), nuclear factor-kB (NF-kB), programmed death-ligand 1(PDL1), and prostate-specific membrane antigen (PSMA) (Hashemi et al., 2020 ). Aptamers are similar to antibodies in terms of their high sensitivity and specificity as targeting agents.…”

Section: Approaches For Target-specific Drug Deliverymentioning

confidence: 99%

Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems

et al. 2022

View full text Add to dashboard Cite

Conventional chemotherapy lacking target selectivity often leads to severe side effects, limiting the effectiveness of chemotherapy. Therefore, drug delivery systems ensuring both selective drug release and efficient intracellular uptake at the target sites are highly demanded in chemotherapy to improve the quality of life of patients with low toxicity. One of the effective approaches for tumor-selective drug delivery is the adoption of functional ligands that can interact with specific receptors overexpressed in malignant cancer cells. Various functional ligands including folic acid, hyaluronic acid, transferrin, peptides, and antibodies, have been extensively explored to develop tumor-selective drug delivery systems. Furthermore, cell-penetrating peptides or ligands for tight junction opening are also actively pursued to improve the intracellular trafficking of anticancer drugs. Sometimes, multiple ligands with different roles are used in combination to enhance the cellular uptake as well as target selectivity of anticancer drugs. In this review, the current status of various functional ligands applicable to improve the effectiveness of cancer chemotherapy is overviewed with a focus on their roles, characteristics, and preclinical/clinical applications.

show abstract

Aptamer-conjugated PLGA nanoparticles for delivery and imaging of cancer therapeutic drugs

Cited by 50 publications

References 116 publications

A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives

A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives

Tumor targetable and pH-sensitive polymer nanoparticles for simultaneously improve the Type 2 Diabetes Mellitus and malignant breast cancer

Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems

Contact Info

Product

Resources

About